March 28, 2017 : DCMS #338

DISASTERS AVERTED — Near Miss Case Studies

 Sometimes It Takes a Disaster to Prevent a Bigger Disaster

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Michael Hill Part 1, 670G Intro

HOMERUN SLIDES — Great Clinical Presentation Highlights

Albuminuria Presentation Part 4

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #68: Regulation of Glucose Metabolism in Liver Part 4 of 11

MOST POPULAR ARTICLES OF THE MONTH

#1 Health Benefits from Intermittent Fasting
#2 The Future For Insulin Pump Companies: Who Will Survive?
#3 New ADA 2017 Standards of Medical Care in Diabetes

It seems that the do-all, fix-all, be-all for kidney problems is either an ARB or ACE-I. We start patients on these medications at the first sign of elevated glucose levels regardless of their blood pressure levels, as they “protect” the kidneys. This is definitely true, but what do we do once kidney disease develops? This week, to answer that question, we continue our Homerun Slides series with a look at therapeutic approaches besides RAS blockade.

Today is American Diabetes Association Alert Day®, the annual opportunity to sound the alarm about the prevalence of type 2 diabetes risk in America. An estimated 86 million American adults—about one in three—are at risk for type 2 diabetes, but 90% of them don’t know it. You can help raise awareness of the risk by sharing the link to the one-minute Type 2 Diabetes Risk Test (you can also download a printable version to share in your office), or share about Alert Day online using #DiabetesAlertDay.

Dave Joffe

Editor-in-chief

This patient was newly diagnosed, but I did not really think she believed she had diabetes. In other words, she was in denial. Once she saw the results of her labs, I could see things changed in her. She “got it.”

In part 1 of this Exclusive Interview, Michael Hill discusses the release of the hybrid closed-loop system, the Minimed 670G.

In this week’s Homerun Slides, therapeutic approaches for chronic kidney disease beyond Renin-angiotensin system (RAS) blockade.

Gluconeogenic pathways: Gluconeogenesis is the synthesis of glucose from three carbon precursors such as alanine, pyruvate, lactate, and glycerol and is essentially a reversal of glycolysis. Under normal conditions, 90% of gluconeogenesis occurs in liver, and the rest occurs mainly in the renal cortex. Other sites of gluconeogenesis, such as the small intestine have been suggested but remain controversial.

Fasting shown to reduce risk of diabetes, heart disease, cancer and other diseases.

As problems for Tandem continue, and with Johnson & Johnson abandoning the insulin pump market, it’s beginning to dawn on some people that we soon could live in a world with just two insulin pump companies – Medtronic and Insulet.

Psychological health, access to care, expanded and personalized treatment options and the tracking of hypoglycemia emphasized.